

Ipca Laboratories

Estimate change



TP change



Rating change



Bloomberg	IPCA IN
Equity Shares (m)	254
M.Cap.(INRb)/(USDb)	378.2 / 4.4
52-Week Range (INR)	1758 / 1052
1, 6, 12 Rel. Per (%)	-5/11/23
12M Avg Val (INR M)	704

Financials & Valuations (INR b)

Y/E March	FY25E	FY26E	FY27E
Sales	89.1	100.8	117.0
EBITDA	17.1	20.9	24.7
Adjusted PAT	8.7	11.6	14.3
EBIT Margin (%)	14.7	16.7	17.6
Cons. Adj EPS (INR)	34.3	45.8	56.5
EPS Gr. (%)	65.1	33.4	23.4
BV/Sh. (INR)	278.8	317.7	365.7

Ratios

Net D-E	0.1	0.0	-0.1
RoE (%)	13.0	15.4	16.5
RoCE (%)	12.4	14.2	15.4
Payout (%)	21.3	16.8	19.0

Valuation

P/E (x)	43.4	32.6	26.4
EV/EBITDA (x)	22.2	18.2	15.4
Div. Yield (%)	0.5	0.5	0.7
FCF Yield (%)	2.1	2.0	2.7
EV/Sales (x)	4.3	3.8	3.2

Shareholding pattern (%)

As On	Dec-24	Sep-24	Dec-23
Promoter	44.7	46.3	46.3
DII	35.7	34.2	34.5
FII	11.1	10.8	10.3
Others	8.5	8.6	8.9

FII Includes depository receipts

CMP: INR1,491

TP: INR1,940 (+30%)

Buy

India and Unichem fuel profitable growth

Efforts in progress to improve business prospects across segments

- Ipca Laboratories (IPCA) delivered a better-than-expected performance in 3QFY25. It has consistently outperformed the industry in the domestic formulation (DF) market. However, this was partly offset by muted business in the South African market. The API prices have been stable, and inventories are moving towards normalized quantum at the industry level.
- We raise our earnings estimates by 4%/3%/2% for FY25/FY26/FY27 factoring in: 1) the increased share of higher-margin products, 2) better operating leverage for the US business of both IPCA and Unichem, and 3) a revival in the South African business. We value IPCA at 36x 12M forward earnings to arrive at our TP of INR1,940 on a 12M forward earnings basis.
- IPCA remains on track to: a) revive the US business from its own site as well as integrate/scale Unichem operations, b) increase offerings/enhance reach/gain market share in the DF segment, c) drive improvement in operating leverage. We model a 28% earnings CAGR over FY25-27. **Reiterate BUY.**

Better segmental mix partly offset by higher opex on a YoY basis

- IPCA's 3QFY25 sales grew 9.4% YoY to INR22.5b (our est: INR22.9b). DF sales grew 12.5% YoY to INR8.8b (39% of total sales). Exports formulation sales increased 5.8% YoY to INR4.6b (20% of total sales). Exports-branded sales rose 52.7% YoY to INR1.6b. Exports-generics sales dipped 11% YoY to INR2.2b. Exports-institutional sales declined 3.1% YoY to INR741m. API sales grew 11.6% YoY to INR3.2b (14% of sales).
- Revenue from subsidiaries grew 2% YoY to INR5.8b (23% of sales). The revenue growth is largely due to Unichem.
- Gross margin (GM) expanded 420bp YoY to 70.2%, due to superior product mix/lower RM costs.
- In line with gross margin, EBITDA margin expanded 450bp YoY to 20.6% (our est: 17.8%), as lower employee expenses (70bp YoY as a % of sales) were partly offset by higher other expenses (+40bp YoY as a % of sales).
- EBITDA rose 40% YoY to INR4.6b (our est: INR4.1b).
- Adj. PAT for the company grew 122.5% YoY to INR2.5b (our est: INR2.0b).
- Revenue/EBITDA/PAT grew 17.9%/31.7%/54.4% YoY in 9MFY25.

Highlights from the management commentary

- IPCA guided a standalone EBITDA margin of 23-24% and a consolidated EBITDA margin of 19.0-19.5% for FY25.
- GM for 3QFY25 was high due to a reduction in material costs. While the pricing was stable, a better product mix led to better GM. The chronic portfolio has done well, driving better GM.
- The Generics business was hit mainly by lower off-take for the South African market (INR1.2b to INR400m sales on an annualized basis). This was largely due to the loss of tender. Significant improvement is likely in FY26.
- IPCA reported volume growth of 6-7% and the price hike was 5-6% YoY for the quarter.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst - Akash Manish Dobhada (Akash.Dobhada@MotilalOswal.com) | **Viraj Shah** (Viraj.Shah@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Quarterly Performance

(INR m)

Y/E March	FY24				FY25E				FY24	FY25E	FY25E	% Chg
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	
Net Revenues (Core)	15,876	20,340	20,529	20,330	20,926	23,549	22,454	22,187	77,074	89,116	22,929	-2.1
YoY Change (%)	0.1	27.0	32.8	34.5	31.8	15.8	9.4	9.1	23.2	15.6	11.7	
EBITDA	2,941	3,606	3,310	3,219	3,927	4,425	4,631	4,128	13,076	17,110	4,081	13.5
YoY Change (%)	3.8	32.4	42.7	77.9	33.5	22.7	39.9	28.2	33.3	30.9	23.3	
Margins (%)	18.5	17.7	16.1	15.8	18.8	18.8	20.6	18.6	17.0	19.2	17.8	
Depreciation	693	903	995	981	989	1,004	985	990	3,572	3,967	995	
EBIT	2,249	2,702	2,315	2,238	2,938	3,421	3,646	3,137	9,503	13,143	3,086	18.1
YoY Change (%)	1.4	29.6	40.0	100.7	30.7	26.6	57.5	40.2	32.0	38.3	33.3	
Margins (%)	14.2	13.3	11.3	11.0	14.0	14.5	16.2	14.1	12.3	14.7	13.5	
Interest	314	441	334	294	241	226	168	147	1,383	781	230	
Other Income	449	386	225	16	206	263	201	230	1,075	900	235	
PBT before EO Expense	2,383	2,647	2,205	1,960	2,904	3,458	3,679	3,220	9,195	13,261	3,091	
One-off (gain)/ Expense	-135	393	-684	1,194	0	0	0	0	769	0	0	
PBT after EO Expense	2,518	2,254	2,889	766	2,904	3,458	3,679	3,220	8,426	13,261	3,091	
Tax	856	879	662	737	914	994	906	1,098	3,135	3,912	927	
Rate (%)	34.0	39.0	22.9	96.2	31.5	28.7	24.6	34.1	34.1	29.5	30.0	
Reported PAT	1,662	1,374	2,227	29	1,990	2,464	2,773	2,122	5,292	9,349	2,164	28.2
Minority Interest	-34	76	-428	-598	-67	-160	-292	-123	-984	-642	-180	
Adj PAT after Minority Int	1,539	1,690	1,115	930	1,922	2,305	2,481	1,999	5,274	8,707	1,984	25.1
YoY Change (%)	0.9	-9.2	-6.1	32.7	24.9	36.4	122.5	114.9	0.0	65.1	77.9	
Margins (%)	9.7	8.3	5.4	4.6	9.2	9.8	11.1	9.0	6.8	9.8	8.7	

Key performance Indicators

Y/E March	FY24				FY25E				FY24	FY25E	FY25E
INR m	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE
Domestic formulations	7,827	8,450	7,796	6,898	8,734	9,405	8,772	7,623	30,972	34,533	8,677
YoY Change (%)	14.3	10.4	11.0	13.5	11.6	11.3	12.5	10.5	12.2	11.5	11.3
Exports formulations	3,979	4,707	4,331	4,737	3,954	5,415	4,582	5,370	17,753	19,320	5,378
YoY Change (%)	-1.0	16.4	8.2	9.5	-0.6	15.0	5.8	13.4	8.3	8.8	24.2
API sales	2,951	3,349	2,850	3,343	2,880	3,186	3,179	3,285	12,493	12,530	3,212
YoY Change (%)	-21.3	9.0	-11.6	-3.6	-2.4	-4.9	11.6	-1.7	-9.3	0.3	12.7
Cost Break-up											
RM Cost (% of Sales)	32.5	33.3	34.0	33.7	30.8	32.2	29.8	30.4	33.4	30.8	33.0
Staff Cost (% of Sales)	22.5	20.9	22.4	22.9	23.3	21.7	21.6	22.3	22.2	22.2	22.2
Other Cost (% of Sales)	26.5	28.0	27.6	27.5	27.2	27.4	28.0	28.6	27.5	27.8	27.0
Gross Margin (%)	67.5	66.7	66.0	66.3	69.2	67.8	70.2	69.6	66.6	69.2	67.0
EBITDA Margin (%)	18.5	17.7	16.1	15.8	18.8	18.8	20.6	18.6	17.0	19.2	17.8
EBIT Margin (%)	14.2	13.3	11.3	11.0	14.0	14.5	16.2	14.1	12.3	14.7	13.5

E: MOFSL Estimates



Highlights from the management commentary

- IPCA shipped four products and seven to eight products are in the pipeline for the US market.
- IPCA's Acute segment reported YoY sales growth of 8.7% vs. +6.0% for IPM in 3Q.
- IPCA posted a sales growth of 17.1% YoY for the Chronic segment vs. +9.7% for IPM in 3QFY25.
- Backward integration, using IPCA API for Unichem formulation, to start reflecting in a couple of quarters.
- API segment has scope to grow 8-10% YoY. The Dewas facility started and running at 30-35% capacity utilization.
- Unichem – 3 / 4 product launches can be expected on an annual basis for the next 4-5 years. Unichem would not need any further formulation capacity

expansion over the next 4-5 years. IPCA would also file 5-6 ANDAs every year going forward.

- The Zerodol portfolio continues to grow well. However, it was offset partly by subdued growth in anti-malaria, infective, and cough & cold.
- IPCA's MR strength stood at ~6,700 in 3QFY25 (vs. 6,300 in 3QFY24) with per month MR productivity of INR0.45m in 9MFY25 vs. INR0.43m in 9MFY24. Going ahead, the company expects per month productivity improvement of INR25-30k
- Expected to add 300MR in the cardiology segment and add one more division in dermatology/cosmetology to sustain industry outperformance in the DF segment.
- ETR- 27-28% for FY25.

Enhancing scope to deliver sustainable growth/margins

Superior execution/additional MR force to drive the DF segment

- In 9MFY25, the DF segment grew 11.8% YoY to INR26.9b, led by growth across key therapies.
- IPCA's top therapy, i.e., pain, contributed ~39% of total revenue and grew 10% in 3QFY25. Cardiac therapy (13% of DF sales) grew 12.8% YoY for 3QFY25. While Derma contributes 6% of DF sales, it has grown at a phenomenal rate of 19.4% YoY for 3QFY25.
- Additionally, IPCA continues to implement efforts toward increasing its field-force productivity.
- Accordingly, we expect 14% sales CAGR in the DF segment to INR44.9b over FY25-27, led by increased traction in key therapies and MR productivity.

Portfolio expansion/synergies with Unichem to drive export growth

- During 9MFY25, IPCA's export sales grew 7.2% YoY to INR13.9b, led by ~32% YoY growth in the institutional business, followed by 14% YoY growth in the branded formulation business. This was partly offset by a 2% YoY decline in the generic business.
- Subsidiary sales grew 59% YoY to INR16.5b, primarily led by ~13% YoY growth in Unichem sales to INR14.4b.
- Product launches and increasing synergy between operations of IPCA and Unichem are likely to improve overall prospects of the US generics over the next 2-3 years.
- Accordingly, we expect the overall export formulations (including Unichem) business to clock 15% sales CAGR to reach INR55b over FY25-27.

Cost efficiency to propel market share gains in the API segment

- During 9MFY25, API sales grew 7.2% YoY to INR14b due to a stable pricing environment.
- IPCA continues to gain market share in its key product, arresting the impact of price decline to some extent.
- With new introductions and improved cost efficiency, we expect a 14.3% sales CAGR in this segment to INR16.4b over FY25-27.

Valuation and view

- We raise our earnings estimates by 4%/3%/2% for FY25/FY26/FY27 factoring in: 1) the increased share of higher-margin products, 2) better operating leverage for the US business of both IPCA and Unichem, and 3) a revival in the South African business. We value IPCA at 36x 12M forward earnings to arrive at our TP of INR1,940 on a 12M forward earnings basis.
- IPCA remains on track to: a) revive the US business from its own site as well as integrate/scale Unichem operations, b) increase offerings/enhance reach/gain market share in the DF segment, c) drive improvement in operating leverage. We model a 28% earnings CAGR over FY25-27. **Reiterate BUY.**

IPCA Ex-Unichem	FY25			FY24		
	IPCA consol	Unichem (3QFY25)	IPCA ex-Unichem	IPCA consol	Unichem (3QFY25)	IPCA ex-Unichem
Gross Sales	22,454	5,331	17,123	20,529	4,344	16,185
YoY Change (%)	32.8	22.7	5.8	32.8	43.6	
Gross Profit	15,772	3,580	12,191	13,559	2,405	11,155
Margins (%)	70.2	67.2	71.2	66.0	55.4	68.9
EBITDA	4,631	855	3,776	4,631	381	4,250
Margins (%)	20.6	16.0	22.1	22.6	8.8	26.3
Depreciation	985	305	679	995	279	716
Interest	168	68	101	334	56	278
Other Income	201	136	65	225	113	112
PBT before EO expense	3,679	618	3,061	2,205	160	3,367
Extra-Ord expense	0	0	0	-684	-680	-4
PBT	3,679	618	3,061	2,889	840	2,049

Exhibit 1: P/E chart






Exhibit 2: EV/EBITDA chart




Story in charts

Exhibit 3: Total sales grew 9.4% YoY in 3QFY25




Source: Company, MOFSL

Exhibit 4: DF sales grew 12.5% YoY in 3QFY25




Source: Company, MOFSL

Exhibit 5: Export formulation sales grew 5.8% YoY in 3QFY25




Source: Company, MOFSL

Exhibit 6: API sales grew 11.6% YoY in 3QFY25




Source: Company, MOFSL

Exhibit 7: EBITDA margin improved 450bp YoY in 3QFY25




Source: Company, MOFSL

Exhibit 8: Expect 23% sales CAGR over FY24-26




Source: Company, MOFSL

Exhibit 9: Expect 13% DF sales CAGR over FY25-27




Source: Company, MOFSL

Exhibit 10: Expect margin to expand over FY25-27



Source: Company, MOFSL

Exhibit 11: Expect return ratios to improve over FY25-27



Source: Company, MOFSL

Financials and valuations

Income Statement							(INR m)		
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Net Revenues	37,732	46,487	54,200	58,298	62,569	77,074	89,116	1,00,752	1,17,043
Change (%)	14.9	23.2	16.6	7.6	7.3	23.2	15.6	13.1	16.2
EBITDA	7,170	9,580	15,444	13,509	9,812	13,076	17,110	20,856	24,696
Change (%)	57.7	33.6	61.2	-12.5	-27.4	33.3	30.9	21.9	18.4
Margin (%)	19.0	20.6	28.5	23.2	15.7	17.0	19.2	20.7	21.1
Depreciation	1,824	2,105	2,092	2,324	2,616	3,572	3,967	4,059	4,150
EBIT	5,346	7,475	13,352	11,184	7,197	9,503	13,143	16,797	20,546
Int. and Finance Charges	189	165	90	77	455	1,383	781	457	430
Other Income - Rec.	483	578	457	666	1,151	1,075	900	950	980
PBT before EO Expense	5,640	7,888	13,719	11,773	7,892	9,195	13,261	17,290	21,096
EO Expense/(Income)	157	445	-171	416	314	769	0	0	0
PBT after EO Expense	5,483	7,442	13,890	11,357	7,579	8,426	13,261	17,290	21,096
Current Tax	1,218	1,406	2,487	2,070	2,302	3,102	3,647	4,876	5,991
Deferred Tax	-176	-53	-85	178	230	33	265	346	422
Tax	1,042	1,353	2,401	2,248	2,532	3,135	3,912	5,222	6,413
Tax Rate (%)	18.5	17.2	17.5	19.1	32.1	34.1	29.5	30.2	30.4
Reported PAT	4,441	6,090	11,488	9,110	5,047	5,291	9,348	12,067	14,682
Less: Minority Interest	18	78	91	269	-206	984	642	450	350
Net Profit	4,423	6,012	11,398	8,841	5,253	4,307	8,707	11,617	14,332
Adj PAT	4,580	6,485	11,255	9,218	5,275	5,274	8,707	11,617	14,332
Adj PAT growth (%)	91.3	41.6	73.6	-18.1	-42.8	0.0	65.1	33.4	23.4

Balance Sheet							(INR m)		
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Equity Share Capital	252	252	254	254	254	254	254	254	254
Total Reserves	30,971	35,903	46,763	54,666	58,167	63,068	70,469	80,345	92,528
Net Worth	31,224	36,275	47,017	54,920	58,420	63,322	70,723	80,599	92,782
Deferred liabilities	1457	1398	1316	1506	1856	3062	3328	3673	4095
Total Loans	3,505	4,328	1,988	8,027	14,746	14,274	11,774	11,067	10,431
Capital Employed	36,342	42,137	50,466	65,222	75,755	94,607	99,998	1,09,512	1,21,480
Gross Block	26,657	30,268	31,872	37,647	43,601	65,195	66,695	68,195	69,695
Less: Accum. Deprn.	6,951	9,056	11,148	13,472	16,088	19,660	23,627	27,686	31,837
Net Fixed Assets	19,706	21,212	20,724	24,175	27,514	45,535	43,068	40,509	37,859
Capital WIP	361	708	2,348	3,064	1,404	3,429	3,429	3,429	3,429
Investments	1,204	2,719	4,711	9,892	6,260	8,620	8,620	8,620	8,620
Curr. Assets	24,217	27,939	32,881	39,237	51,051	53,386	59,286	73,792	92,737
Inventory	10,725	13,231	15,948	18,580	17,434	24,713	24,904	29,812	35,594
Account Receivables	6,815	8,952	8,118	9,108	9,890	16,865	17,823	21,531	25,653
Cash and Bank Balance	2,823	1,809	3,651	6,407	18,532	2,968	6,338	10,895	18,066
Loans & Advances	3,854	3,947	5,164	5,143	5,194	8,840	10,221	11,555	13,424
Curr. Liability & Prov.	9,147	10,441	10,198	11,147	10,473	16,364	14,405	16,838	21,164
Account Payables	8,190	9,182	8,781	9,704	8,923	13,050	12,696	14,906	18,919
Provisions	957	1,259	1,417	1,443	1,550	3,314	1,709	1,932	2,245
Net Current Assets	15,070	17,498	22,682	28,091	40,577	37,022	44,881	56,954	71,573
Appl. of Funds	36,342	42,137	50,466	65,222	75,755	94,607	99,998	1,09,512	1,21,480

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Adj. EPS (INR)	18.1	25.6	44.4	36.3	20.8	20.8	34.3	45.8	56.5
Cash EPS	24.8	32.2	53.2	44.0	31.0	31.1	50.0	61.8	72.8
BV/Share	123.7	143.2	185.3	216.5	230.3	249.6	278.8	317.7	365.7
DPS	0.5	3.6	6.8	6.6	7.7	7.8	7.9	8.1	11.1
Payout (%)	2.8	14.8	14.9	18.3	38.3	36.9	21.3	16.8	19.0
Valuation (x)									
P/E	82.6	58.3	33.6	41.0	71.7	71.7	43.4	32.6	26.4
P/BV	12.1	10.4	8.0	6.9	6.5	6.0	5.3	4.7	4.1
EV/Sales	10.1	8.2	7.0	6.5	6.1	4.9	4.3	3.8	3.2
EV/EBITDA	53.0	39.7	24.6	28.1	38.7	29.1	22.2	18.2	15.4
Dividend Yield (%)	0.0	0.2	0.5	0.4	0.5	0.5	0.5	0.5	0.7
Return Ratios (%)									
RoE	15.8	19.2	27.1	18.1	9.3	8.7	13.0	15.4	16.5
RoCE	14.3	17.7	25.4	17.1	8.3	9.2	12.4	14.2	15.4
RoIC	14.0	18.0	28.7	21.1	10.2	9.7	11.5	13.9	16.1
Working Capital Ratios									
Fixed Asset Turnover (x)	1.9	2.3	2.6	2.6	2.4	2.1	2.0	2.4	3.0
Debtor (Days)	65	70	54	56	58	80	73	78	80
Inventory (Days)	104	104	107	116	102	117	102	108	111
Working Capital Turnover (Days)	118	123	128	136	129	161	158	167	167
Leverage Ratio (x)									
Interest Cover Ratio	28.3	45.3	147.7	145.4	15.8	6.9	16.8	36.8	47.8
Debt/Equity	0.0	0.1	0.0	0.0	-0.1	0.2	0.1	0.0	-0.1

Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Oper. Profit/(Loss) before Tax	7,170	9,580	15,444	13,509	9,812	13,076	17,110	20,856	24,696
Interest/Dividends Recd.	483	578	457	666	1,151	1,075	900	950	980
Direct Taxes Paid	-1,165	-1,412	-2,484	-2,058	-2,181	-1,928	-3,647	-4,876	-5,991
(Inc)/Dec in WC	-1,686	-3,442	-3,343	-2,652	-361	-12,009	-4,489	-7,517	-7,447
CF from Operations	4,803	5,304	10,075	9,464	8,421	213	9,875	9,413	12,238
Others	365	784							
EO Expense / (Income)	157	445	-171	416	314	769	0	0	0
CF from Oper. incl EO Exp.	5,010	5,643	10,246	9,048	8,107	-556	9,875	9,413	12,238
(inc)/dec in FA	-1,632	-3,958	-3,244	-6,491	-4,294	-23,618	-1,500	-1,500	-1,500
Free Cash Flow	3,379	1,685	7,002	2,557	3,813	-24,174	8,375	7,913	10,738
(Pur)/Sale of Investments	-336	-1,515	-1,992	-5,181	3,632	-2,360	0	0	0
Others	317	376	0	0	0	0	0	0	0
CF from Investments	-1,651	-5,097	-5,236	-11,672	-662	-25,979	-1,500	-1,500	-1,500
Issue of shares	0	0	1	0	0	0	0	0	0
(Inc)/Dec in Debt	-1,070	804	-2,331	6,663	6,683	12,743	-2,275	-707	-636
Interest Paid	-189	-165	-90	-77	-455	-1,383	-781	-457	-430
Dividend Paid	-126	-902	-1,710	-1,670	-1,933	-1,950	-1,989	-2,029	-2,790
Others	-447	-1,042	961	306	386	1,294	39	1,068	1,168
CF from Fin. Activity	-1,832	-1,305	-3,169	5,222	4,681	10,705	-5,007	-2,125	-2,688
Inc/Dec of Cash	1,528	-758	1,841	2,598	12,126	-15,830	3,368	5,788	8,049
Add: Beginning Balance	2,181	3,709	2,954	4,795	7,393	19,519	2,968	6,334	10,895
Forex/ Business acquisition	0	3	0	0	0	0	0	0	0
Closing Balance	3,709	2,954	4,795	7,393	19,519	3,689	6,336	12,123	18,944
Bank balances / Mutual fund (gain)/ loss	-886	-1,145	-1,145	-986	-986	-721	-2	1,228	878
Closing Balance	2,823	1,809	3,650	6,407	18,533	2,968	6,334	10,895	18,066

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA.

Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.

7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.